Oryzon Strengthens Patent Portfolio for Iadademstat and Vafidemstat
Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company recognized for its contributions to the field of epigenetics, has made significant strides in enhancing its patent portfolio related to iadademstat and vafidemstat. These clinical-stage LSD1 inhibitors are pertinent to the treatment of oncology and central nervous system (CNS) disorders. The latest developments stem from new Decisions to Grant received from both the Australian and European patent offices, marking a pivotal moment for the company.
Recent Patent Grants
The Australian Patent Office has recently issued a Decision to Grant for Oryzon’s patent application AU2020249493, which is centered on "Combinations of iadademstat for cancer therapy." This grant covers innovative combinations of iadademstat and PD1 or PD-L1 inhibitors aimed at treating cancer, including small cell lung cancer (SCLC). This patent, when granted, is projected to remain effective until at least the year 2040, pending any potential extensions. Furthermore, a corresponding patent has been approved in Russia, with ongoing applications in Europe, the U.S., Japan, China, and other locations.
Iadademstat Clinical Trials
Currently, iadademstat is being investigated in an advanced Phase I/II trial in partnership with the U.S. National Cancer Institute (NCI). This trial focuses on patients with extensive SCLC and includes the use of PD-L1 inhibitors, such as atezolizumab or durvalumab. Notably, more than 30 renowned medical institutions throughout the U.S., including esteemed centers like Memorial Sloan Kettering and Johns Hopkins, are participating in this collaborative trial.
Expansion of Vafidemstat's Patent Rights
In addition to advancements with iadademstat, Oryzon has also received a Decision to Grant from the European Patent Office for its patent application EP24205125.8. This patent, aimed at using vafidemstat for addressing behavior alterations, includes claims for treating aggressiveness and social withdrawal linked to various CNS diseases. Substantially, the patent covers aggressive behaviors associated with conditions such as Borderline Personality Disorder (BPD), Autism Spectrum Disorder (ASD), and Alzheimer’s disease. Once formally granted, this patent will be effective until at least 2038, excluding any applicable extensions.
Clinical Development of Vafidemstat
Vafidemstat is on the brink of major trials dedicated to psychiatric disorders. It is preparing for a Phase III trial focused on aggressiveness in patients with BPD, and a Phase II trial is on the horizon for aggression related to ASD. Alongside this, a Phase II trial is actively exploring treatment for schizophrenia with a focus on negative symptoms like social withdrawal. These strategic clinical developments are part of Oryzon's commitment to advancing treatment modalities for complex conditions.
Strengthening Intellectual Property Position
Neus Virgili, Oryzon’s Chief IP Officer, commented on the significance of these new patent grants, stating that they effectively bolster Oryzon’s global intellectual property position. These patents play a crucial role in safeguarding essential therapeutic avenues currently under clinical development for their respective compounds. This move is expected to extend the commercial viability of both iadademstat and vafidemstat.
About Oryzon Genomics
Founded in 2000 in Barcelona, Oryzon is at the forefront of epigenetic research, focusing on personalized medical solutions for CNS disorders and oncology. With a proficient team split between Barcelona, Boston, and San Diego, Oryzon maintains a robust clinical portfolio comprised of two LSD1 inhibitors, with vafidemstat being Phase III-ready for CNS applications and iadademstat presently in Phase II trials for oncology indications.
In addition to its lead compounds, Oryzon is expanding its research horizons with emerging candidates aimed at targeting different epigenetic mechanisms, like HDAC-6 with ORY-4001. With a dedicated platform for biomarker identification and validation, Oryzon is poised to address several malignant and neurological diseases efficiently. To learn more about Oryzon, more information can be found at www.oryzon.com
Frequently Asked Questions
What are iadademstat and vafidemstat?
These are clinical-stage LSD1 inhibitors being developed by Oryzon for the treatment of various cancers and CNS disorders.
How will the new patent grants affect Oryzon?
The new patents strengthen Oryzon's intellectual property rights, protecting its innovations and extending the commercial viability of its products.
What is currently happening with iadademstat trials?
The iadademstat trial is ongoing in partnership with the NCI, focusing on patients with extensive small cell lung cancer.
What conditions are targeted by vafidemstat?
Vafidemstat aims to treat aggressiveness and social withdrawal associated with conditions like BPD, ASD, and schizophrenia.
Where can I find more information about Oryzon?
Detailed information about the company and its initiatives can be found on their website at www.oryzon.com.
